Frontiers in Immunology, 2019 The successful generation of T cell-mediated immunity for the treatment of cancer has been a major focal point of research. One of the critical strategies of cancer immunotherapy is to efficiently activate antigen-specific CD8 T cells in the ...
Jin-Zhi Lai +5 more
doaj +1 more source
Adoptive B cell therapy for chronic viral infection
Frontiers in Immunology, 2022 T cell-based therapies have been widely explored for the treatment of cancer and chronic infection, but B cell-based therapies have remained largely unexplored.
Young Rock Chung +4 more
doaj +1 more source
Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12 [PDF]
, 2011 Immunotherapy-based strategies for gastrointestinal carcinomas (GIC) have been exploited so far, but these approaches have to face strong mechanisms of immune escape induced by tumours.
Alaniz +69 more
core +1 more source
Adoptive T-Cell Therapy for Cancer [PDF]
, 2016 Recent developments have demonstrated that immunotherapies are capable of achieving durable antitumor responses in patients with metastatic cancer. One modality that has been able to induce durable complete regressions in patients with melanoma has been adoptive cell therapy (ACT).
James C, Yang, Steven A, Rosenberg
openaire +2 more sources
Study protocol for THINK : a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types [PDF]
, 2017 Introduction: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3 zeta signalling domain, which associates with the adaptor ...
Aftimos, Philippe +15 more
core +1 more source
Frontiers in Oncology, 2022 Peripheral T-cell lymphoma (PTCL) is a type of highly heterogeneous non-Hodgkin lymphoma with a poor prognosis and lack of effective targeted therapies. Adoptive T-cell therapy has been successfully used in the treatment of B-cell malignancies.
Yuan Chen +6 more
doaj +1 more source
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. [PDF]
, 2018 Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of
Avanzi, Mauro P +10 more
core +1 more source
Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma
Frontiers in Veterinary Science, 2021 Osteosarcoma is the most common primary bone tumor in both humans and dogs. It is a highly metastatic cancer and therapy has not improved significantly since the inclusion of adjuvant chemotherapy into disease treatment strategies.
William C. Kisseberth, Dean A. Lee
doaj +1 more source
Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. [PDF]
, 2015 Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists.
Biassoni +67 more
core +1 more source
Frontiers in Immunology, 2023 Recurrent neoepitopes are cancer-specific antigens common among groups of patients and therefore ideal targets for adoptive T cell therapy. The neoepitope FSGEYIPTV carries the Rac1P29S amino acid change caused by a c.85C>T missense mutation, which is
Lena Immisch +15 more
doaj +1 more source